MEMOTEXT to present at both Washington D.C.’s Health Datapalooza 2015 and Pittsburgh’s SMA 2015 this week
Washington, D.C. June 1, 2015 – MEMOTEXT Corp. announces today the upcoming presentation of the Balanced Adherence Metric (BAM). The BAM will be presented tomorrow by MEMOTEXT’s Director of Scientific Development Bill Simpson, Ph.D. Candidate in Neuroscience, at the inaugural Science of Medication Adherence conference (SMA 2015) at the University of Pittsburgh. MEMOTEXT also has a delegation at Washington D.C.’s Health Datapalooza 2015 including Founder and President of MEMOTEXT Amos Adler, M.Sc. Health Datapalooza 2015 runs from today until Wednesday and MEMOTEXT will be present for the entire duration.
Attendees can expect to learn about a successful collaborative case study in digital health personalization and adherence engagement
Posted on May 28, 2015 by Noah Nemoy
PerformRx and MEMOTEXT Corp. are pleased to announce their joint presentation on HealthNHandSM at the Consulate General of Canada’s The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar in Philadelphia, on June 15th. HealthNHand is being cited as successful case study, in both digital health personalization and adherence engagement.
MEMOTEXT Validates the Balanced Adherence Metric (BAM)
Posted on May 28, 2015 by Noah Nemoy
Finding ways to accurately measure medication adherence can be difficult. Currently, most metrics use pharmacy claims data to measure an individual’s adherence. Many academics and professionals use measures like Proportion of Days Covered (PDC) or Medication Possession Ratio (MPR). But while these measures have several advantages, they don’t account for other adherence factors, such as delay to refill and medication persistence. To solve the problem, MEMOTEXT developed the Balanced Adherence Metric (BAM). BAM amalgamates the four most common adherence measures, providing a more accurate and holistic metric.
Posted on May 22, 2015 by Noah Nemoy
Working in the MaRS Centre has a lot of perks: Thought provoking guest lectures from international experts, mentorship, access and support that is second to none. But in this case it was having much of the Centre repurposed to host HealthKick2015 on May 6th and 7th.
Updated on April 6, 2015 by Noah Nemoy
MEMOTEXT is honored that our patient adherence solutions have been selected as a finalist for the 3rd Annual Scattergood Foundation Innovation Award! This prestigious award recognizes innovation breakthroughs in the field of behavioral health-care.
Posted on March 11, 2015 by Noah Nemoy
This March 8-15, is World Glaucoma Week. Launched 6 years ago by the World Glaucoma Association and The World Glaucoma Patient Association, events are being held across the world to raise awareness about Glaucoma. Afflicting 9 million people, Glaucoma is the world’s leading cause of irreversible blindness. Due to its slow progression, 50% of patients in the developed world and 90% in the developing world are untreated. While Glaucoma is currently incurable, with early detection and treatment, its progression can be halted.
Posted on February 6, 2015 by Noah Nemoy
The past year has been one of tremendous growth and new opportunities for both MEMOTEXT – one of the pioneering mHealth companies – and mHealth as a whole. The two trends that power the mHealth revolution; increased usage of mobile technology and the move towards decentralized and personalized health care, have continued unabated. While mHealth is an industry still largely in its infancy, the use of this technology will only increase as the gap between the 10% of smartphone owners using health apps and 72% of patients using mobile apps, continues to close.
Posted on February 2, 2015 by Bill Simpson
I am not a medical historian, but I would bet that if you asked one, they would identify the synthesis of Aspirin in 1897 as one of most significant moments in modern medicine. With its pain-relieving, anti-inflammatory and anti-platelet (blood thinning) properties packaged within a single tablet, Aspirin provided a safe, effective and easy treatment for a wide range of illnesses. Even today, it is listed on the World Health Organization’s List of Essential Medicines and is taken daily by millions of people for the prevention of heart attacks and strokes. Its synthesis (and the pharmaceutical revolution it helped to user in) has no doubt helped to increase our lifespan and bring about a higher quality of life.